Literature DB >> 26052391

Hepatocellular carcinoma: From diagnosis to treatment.

Abhijeet Waghray1, Arvind R Murali1, Kv Narayanan Menon1.   

Abstract

Hepatocellular carcinoma (HCC) is the sixth most prevalent malignancy worldwide and is a rising cause of cancer related mortality. Risk factors for HCC are well documented and effective surveillance and early diagnosis allow for curative therapies. The majority of HCC appears to be caused by cirrhosis from chronic hepatitis B and hepatitis C virus. Preventive strategies include vaccination programs and anti-viral treatments. Surveillance with ultrasonography detects early stage disease and improves survival rates. Many treatment options exist for individuals with HCC and are determined by stage of presentation. Liver transplantation is offered to patients who are within the Milan criteria and are not candidates for hepatic resection. In patients with advanced stage disease, sorafenib shows some survival benefit.

Entities:  

Keywords:  Hepatitis C virus; Hepatocellular carcinoma; Liver transplantation; Sorafenib; Tumor ablation

Year:  2015        PMID: 26052391      PMCID: PMC4450179          DOI: 10.4254/wjh.v7.i8.1020

Source DB:  PubMed          Journal:  World J Hepatol


  106 in total

Review 1.  Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

2.  Alpha-1 fetoglobulin in the diagnosis of human hepatoma.

Authors:  M E Alpert; J Uriel; B de Nechaud
Journal:  N Engl J Med       Date:  1968-05-02       Impact factor: 91.245

3.  Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.

Authors:  Jessica Y Leung; Andrew X Zhu; Fredric D Gordon; Daniel S Pratt; Abigail Mithoefer; Kathryn Garrigan; Adam Terella; Martin Hertl; A Benedict Cosimi; Raymond T Chung
Journal:  Liver Transpl       Date:  2004-11       Impact factor: 5.799

4.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

5.  Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma.

Authors:  C Brechot; C Pourcel; A Louise; B Rain; P Tiollais
Journal:  Nature       Date:  1980-07-31       Impact factor: 49.962

6.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 7.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

8.  Liver cancer in Asian migrants to the United States and their descendants.

Authors:  K A Rosenblatt; N S Weiss; S M Schwartz
Journal:  Cancer Causes Control       Date:  1996-05       Impact factor: 2.506

9.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  52 in total

1.  Downregulation of LncRNA GAS5 promotes liver cancer proliferation and drug resistance by decreasing PTEN expression.

Authors:  Congren Wang; Shaoying Ke; Mingzhu Li; Conglin Lin; Xiaoyu Liu; Qunxiong Pan
Journal:  Mol Genet Genomics       Date:  2019-11-08       Impact factor: 3.291

Review 2.  Hepatocellular carcinoma: Where are we?

Authors:  Roberto Mazzanti; Umberto Arena; Renato Tassi
Journal:  World J Exp Med       Date:  2016-02-20

3.  Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria.

Authors:  Mohammed Elshamy; Federico Aucejo; K V Narayanan Menon; Bijan Eghtesad
Journal:  World J Hepatol       Date:  2016-07-28

4.  Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response.

Authors:  Behzad Yeganeh; Adel Rezaei Moghadam; Javad Alizadeh; Emilia Wiechec; Seyed Moayed Alavian; Mohammad Hashemi; Bita Geramizadeh; Afshin Samali; Kamran Bagheri Lankarani; Martin Post; Payam Peymani; Kevin M Coombs; Saeid Ghavami
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

5.  Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.

Authors:  Youcai Li; Jun Zhang; Jiamei Gu; Kongzhen Hu; Shun Huang; Peter S Conti; Hubing Wu; Kai Chen
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

6.  Gas Embolization in a Rodent Model of Hepatocellular Carcinoma Using Acoustic Droplet Vaporization.

Authors:  Jonah S Harmon; Foad Kabinejadian; Robinson Seda; Mario L Fabiilli; Sibu P Kuruvilla; Joan M Greve; Brian J Fowlkes; Joseph L Bull
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2018-07

7.  MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling.

Authors:  Annie Zhang; Jaganathan Lakshmanan; Amirreza Motameni; Brian G Harbrecht
Journal:  Mol Cell Biochem       Date:  2017-09-08       Impact factor: 3.396

Review 8.  AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers.

Authors:  Fuyou Zhang; Jianfa Li; Huizhong Xiao; Yifan Zou; Yuchen Liu; Weiren Huang
Journal:  Cell Prolif       Date:  2017-10-22       Impact factor: 6.831

9.  Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma.

Authors:  Julie M Jiang; Nitin Ohri; Justin Tang; Renee Moadel; Jacob Cynamon; Andreas Kaubisch; Milan Kinkhabwala; Madhur K Garg; Chandan Guha; Rafi Kabarriti
Journal:  J Gastrointest Oncol       Date:  2019-06

Review 10.  Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma.

Authors:  Bijay Dhungel; Aparna Jayachandran; Christopher J Layton; Jason C Steel
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.